SHL buyout looks to advance self-injection drug delivery offering
Drug delivery devices manufacturer SHL announced that it has acquired Weibel, a company conducting R&D on injection devices, aiming to advance patient convenience during auto-injection.
The transaction will see SHL gain access to Weibel’s portfolio of packaging technologies and delivery systems applied on parenteral drugs for use at home, at point of care, and at the clinic.
Ulrich Faessler, SHL’s CEO, stated that the integration of Weibel will strengthen the company’s ability to advance its portfolio of drug delivery systems, focusing on human-centered self-injection designs with improved functionality.
Moreover, the deal is expected to help the acquiring company expand its reach in the self-injection market. Financial terms of the transaction were not disclosed.
Weibel’s offering includes self-injection technologies which integrate all parts needed for reconstitution of the drug in the same device.
The product family known as Reconstyringe is designed to conduct a fully automated reconstitution of lyophilized drugs. The drug is contained in a vial with the solvent in Weibel’s MiniBagSystem. After the reconstitution cycle is completed, the drug is drawn for injection into the SuperCapSyringe.
On its turn, the SuperCapSyringe turns the vial into a prefilled syringe. It has a modular design and comes in different sizes, with staked needles including a safety function.
Finally, the company has designed a cartridge-based patch injector known as LyCaJect, which also conducts automatic reconstitution of lyophilized drugs.
According to the company, integration of all functions enables less time to be required for the treatment administration, while it facilitates the process for patients and their caregivers. Additionally, the automated process helps users avoid injuries, offering a safer administration.
